Back to News
Market Impact: 0.42
Amneal Pharma Gains FDA Approval For Lanreotide Injection
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Amneal Pharmaceuticals received FDA approval for its lanreotide injection, 120 mg/0.5 mL, in a sterile single-dose prefilled syringe. The product references SOMATULINE Depot and is expected to be launched immediately, creating a new approved product opportunity for Amneal in the U.S. market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
AMRX0.78
More News
- Trump vows to create an ‘AI Force’ and nods to justice system after rejecting calls to slow down industry. ‘Rather, we will cherish it’
- Polymarket fraud concerns mount as company prepares for potential IPO
- Australia seeks big tech support for internet safety, AI regulation
- Paramount could settle with states over Warner Bros. as soon as this weekend, sources say
- Trump says he will appoint a new AI adviser, without providing details
- Trump says he will create ‘AI Force’ with new ‘AI czar’